

# CLAIMS

We claim:

- 1 1. A method for preventing or treating Sinusoidal Obstruction Syndrome ("SOS")  
2 comprising administering a matrix metalloproteinase ("MMP") inhibitor.
- 1 2. A method for preventing or treating chemotherapy- or radiation-induced liver  
2 disease comprising administering a matrix metalloproteinase ("MMP") inhibitor.
- 1 3. The method of claim 2, wherein said chemotherapy-induced liver disease includes  
2 SOS, nodular regenerative hyperplasia, peliosis hepatis, immunosuppression-  
3 induced hepatic venoocclusive disease, and sinusoidal dilatation.
- 1 4. The method of claims 1 or 2, wherein said MMP inhibitor is doxycycline or 2-[(4-  
2 biphenylsulfonyl)amino]-3-phenyl-propionic acid.
- 1 5. The method of claim 4, wherein said MMP inhibitor is doxycycline.
- 1 6. The method of claim 5 wherein 15 mg/kg of said doxycycline is administered  
2 twice daily. 564-25-0
- 1 7. The method of claim 4, wherein said MMP inhibitor is 2-[(4-  
2 biphenylsulfonyl)amino]-3-phenyl-propionic acid.
- 1 8. The method of claim 7 wherein 100-200 mg/hour of said 2-[(4-  
2 biphenylsulfonyl)amino]-3-phenyl-propionic acid is administered.
- 1 9. The method of claims 1 or 2 wherein said MMP inhibitor is administered for up to  
2 4 weeks. 154039-60-8
- 1 10. The method of claims 1 or 2, wherein said MMP inhibitor is Marimastat,  
2 Prinomastat, RS-130,830, CGS 27023A, Solimastat, BAY 12-9566, Ro 32-3555,  
3 BMS-272591, Ilomastat, D2163, Metastat, Neovastat, or Periostat. 17633-21-5  
15866-90-7  
305838-77-1
- 1 11. A method for preventing or treating chemotherapy or radiation induced liver  
2 disease comprising administering an effective dose of a matrix metalloproteinase  
3 ("MMP") inhibitor selected from doxycycline or 2-[(4-biphenylsulfonyl)amino]-  
4 3-phenyl-propionic acid.
- 1 12. The method of claim 11, wherein said MMP inhibitor is doxycycline.
- 1 13. The method of claim 12, wherein 15 mg/kg of said doxycycline is administered  
2 twice daily.

- 1  
2  
1  
2  
1  
2  
1  
2  
3
- ✓ 14. The method of claim 11, wherein said MMP inhibitor is 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.
15. The method of claim 14, wherein 100-200 mg/hour of said 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid is administered.
- △ 16. A method for preventing or treating chemotherapy or radiation induced liver disease comprising administering 15 mg/kg of doxycycline twice daily.
17. A method for preventing or treating chemotherapy or radiation induced liver disease comprising administering 100-200 mg/hour of 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.